Disease · MONDO_0005522

small intestine carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. small intestine carcinoma. Diseases, record MONDO_0005522. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005522

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: small intestine carcinoma; Open Targets
Open Targets ID: MONDO_0005522; Open Targets
Other names: carcinoma of small bowel, carcinoma of small intestine, carcinoma of the small bowel, carcinoma of the small intestine, small bowel carcinoma, small intestinal carcinoma, small intestine cancer, NOS; Open Targets
Disease Ontology: DOID:4907; Disease Ontology
NCI Thesaurus: C7724; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 3 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IRINOTECAN HYDROCHLORIDE	CHEMBL3989514	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BINTRAFUSP ALFA	CHEMBL4298024	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENTINOSTAT	CHEMBL27759	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 binding agent	Phase 1/2	https://conductscience.org/library/genes/29126	Drugs and targets
HDAC1	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC10	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC2	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC4	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/10014	Drugs and targets
HDAC6	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/10013	Drugs and targets
HDAC7	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/51564	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00433550	Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer	Phase 2	33	2017-08-24	Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer	CAPECITABINE, IRINOTECAN HYDROCHLORIDE, OXALIPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04708470	A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers	Phase 1/2	55		Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV, Anal Cancer, Cervical Cancer, Penile Cancer, Vulvar Cancer, Vaginal Cancer, Colon Cancer	BINTRAFUSP ALFA, ENTINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT00019773	Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer	Phase 1			Carcinoma of the Appendix, Colorectal Cancer, Small Intestine Cancer	CAPECITABINE, OXALIPLATIN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
14981738	RESULT	1	PubMed
11919233	RESULT	1	PubMed
24114122	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005522

GET https://conductscience.org/api/diseases/v1/MONDO_0005522/drugs

API reference For AI assistants